Does TAFASITAMAB Cause Urinary tract infection? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Urinary tract infection have been filed in association with TAFASITAMAB (MONJUVI). This represents 0.5% of all adverse event reports for TAFASITAMAB.
7
Reports of Urinary tract infection with TAFASITAMAB
0.5%
of all TAFASITAMAB reports
1
Deaths
2
Hospitalizations
How Dangerous Is Urinary tract infection From TAFASITAMAB?
Of the 7 reports, 1 (14.3%) resulted in death, 2 (28.6%) required hospitalization.
Is Urinary tract infection Listed in the Official Label?
Yes, Urinary tract infection is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Urinary tract infection?
ADALIMUMAB (6,375)
LENALIDOMIDE (4,247)
ETANERCEPT (3,915)
OCRELIZUMAB (3,618)
TOFACITINIB (3,179)
METHOTREXATE (2,960)
DALFAMPRIDINE (2,757)
RITUXIMAB (2,579)
CARBIDOPA\LEVODOPA (2,151)
ABATACEPT (2,110)
Which TAFASITAMAB Alternatives Have Lower Urinary tract infection Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR